Evidence map›Paper›PMID 41673885›Full record

ArticleHuman genomics2026

Promoter landscape of maternal plasma DNA reveals predictive signatures of fetal growth restriction.

Jin Wang, Peina Du, Zhiyan Wu, Xiaohan Zhao, Fei Hou, Gang Xin, Shengye Du, Jianhua Kang, Yingying Peng, Wenqiu Xu and 1 more

Abstract readMulticenter Study
In one paragraph

Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jin Wang *Prenatal Diagnosis Center, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, No. 22029 Jing Shi Road, Shizhong District, Jinan, Shandong, 250000, China.
Peina Du *Clin Lab, BGI Genomics, Shanghai, China.
Zhiyan WuDepartment of Gynecology, Qingzhou People's Hospital, Weifang, Shandong, China.
Xiaohan ZhaoPrenatal Diagnosis Center, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, No. 22029 Jing Shi Road, Shizhong District, Jinan, Shandong, 250000, China.
Fei HouPrenatal Diagnosis Center, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, No. 22029 Jing Shi Road, Shizhong District, Jinan, Shandong, 250000, China.
Gang XinDepartment of Obstetrics, The Second Hospital of Shandong University, Jinan, Shandong, China.
Shengye DuDepartment of Obstetrics, Jinan People's Hospital, Jinan, Shandong, China.
Jianhua KangDepartment of Obstetrics, Shanghe County People's Hospital, Jinan, Shandong, China.
Yingying PengPrenatal Diagnosis Center, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, No. 22029 Jing Shi Road, Shizhong District, Jinan, Shandong, 250000, China.
Wenqiu XuClin Lab, BGI Genomics, Shanghai, China.
Hua JinPrenatal Diagnosis Center, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, No. 22029 Jing Shi Road, Shizhong District, Jinan, Shandong, 250000, China. prenatal123@163.com.

Funding

Ji Nan Health High-Caliber Talent Project 202512Science and Technology Development Project of Jinan 202328021Science and Technology Development Project of Jinan 202430065Shandong Province Medical and Health Science and Technology Project 202305020433
6 · The paper itself

Abstract

backgroundFetal growth restriction (FGR) causes serious pregnancy complications, but early detection is challenging. Promoter coverage patterns from maternal plasma cell-free DNA (cfDNA) offer a promising, non-invasive method for early FGR detection.

methodsThis retrospective multicenter study enrolled 788 singleton pregnancies (282 FGR and 506 matched controls) undergoing NIPT blood draw between 12 and 29 weeks of gestation from four hospitals in China. cfDNA promoter coverage was analyzed to identify transcription start site (TSS) features differentially covered in FGR. Feature selection was performed using LASSO regression. Three machine learning models—support vector machine (SVM), logistic regression (LR), and K-nearest neighbor (KNN)—were constructed. Model performance was assessed using area under the ROC curve (AUC), with an internal dataset used for validation. Functional enrichment analysis was conducted for biological interpretation.

resultsA total of 198 differentially covered TSS features were selected. In the validation dataset, both LR and SVM models demonstrated comparable predictive accuracy, with AUCs of 0.7 for LR and 0.69 for SVM. The associated genes were enriched in pathways related to placental and fetal development.

conclusionPromoter profiling of maternal plasma cfDNA represents a novel, non-invasive approach for mid-pregnancy FGR prediction. This method could enhance early detection of at-risk pregnancies and inform clinical decision-making in prenatal care.

Indexed as

Cell-Free Nucleic AcidsFetal Growth RetardationPromoter Regions, GeneticAdultFemaleHumansPregnancyRetrospective StudiesROC CurveSupport Vector MachineTranscription Initiation SiteCell-Free Nucleic AcidsCell-free DNAFetal growth restrictionNIPTPredict

Identifiers

PMID41673885
PMCPMC12997867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.